ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2313

Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis

Christine Loftis1, Liron Caplan2, Joanna Padilla Zepeda3, Nicole Mukooba3, Mayan Caplan3, Meika Fang4, Liya Stolyar5, Jessica Walsh6, Gail Kerr7, Siba Raychaudhuri8, Andreas Reimold9 and Maida Wong10, 1University of Colorado Anschutz School of Medicine, Aurora, CO, 2Univ of Colorado School of Medicine/Rocky Mtn Regional Veterans Affairs Medical Center, Aurora, CO, 3University of Colorado, Aurora, CO, 4Veterans Affairs, Los Angeles, 5Veterans Affairs, Palo Alto, 6Veterans Affairs, Salt Lake City, UT, 7Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 8Veterans Affairs, Sacramento, 9University of Texas Southwestern Medical School, Dallas, 10Veterans Affairs, Long Beach

Meeting: ACR Convergence 2024

Keywords: Disparities, Psoriatic arthritis, race/ethnicity, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Studies have suggested a delay between symptom onset and diagnosis for Psoriatic Arthritis (PsA) and axial spondyloarthritis (axSpA).  Factors that influence this delay have received limited attention.  We examined changes in this delay over the past five decades and clinical predictors of the time to diagnosis for PsA and axSpA, with special attention to possible associations with race and ethnicity.

Methods: Patients with PsA (n=245) and axSpA (n=258) enrolled in the U.S. Department of Veterans Affairs Program to Understand the Long-term Outcomes in SpondyloARthritis (PULSAR) registry self-reported the date of symptom onset for their disease, as well as their race and ethnicity. Race and ethnicity were modeled as independent dichotomous variables to allow for all possible combinations. The date of diagnosis was recorded by the rheumatologist caring for the patient. We performed a multivariate linear regression of diagnostic delay for available clinical variables, including sex, race, ethnicity, smoking status, education level, ESR and CRP concentrations, HLAB27 positivity, and decade of symptom onset. Models were developed using backward stepwise elimination, and only variables with p < 0.05 were retained.  Separate models were constructed for PsA and axSpA.

Results: For both PsA and axSpA, the delay in diagnosis declined by an average of two years over each decade.  No association was identified for any race or ethnicity, except for Hispanics, who experienced an approximately 4.8-year greater diagnostic delay (1766 days) than non-Hispanics.  No other clinical variables examined demonstrated an association with diagnostic delay.

Conclusion: There has been progress in the time required to diagnose individuals with PsA and axSpA over the past few decades.  Individuals self-identifying as Hispanic experienced a longer time to establish a diagnosis of PsA than non-Hispanics—a phenomenon not observed with axSpA.  The reasons for this delay should be further explored.

Supporting image 1

Demographics

Supporting image 2

Linear regression analysis for predictors of diagnostic delay (days) for psoriatic arthritis and axial spondyloarthritis


Disclosures: C. Loftis: None; L. Caplan: None; J. Padilla Zepeda: None; N. Mukooba: None; M. Caplan: None; M. Fang: None; L. Stolyar: None; J. Walsh: None; G. Kerr: AstraZeneca, 1, Boehringer-Ingelheim, 6, Bristol-Myers Squibb(BMS), 1, CSL Behring, 6, Janssen, 6, Novartis, 1, Pfizer, 6, Sanofi, 6, UCB, 1; S. Raychaudhuri: None; A. Reimold: None; M. Wong: None.

To cite this abstract in AMA style:

Loftis C, Caplan L, Padilla Zepeda J, Mukooba N, Caplan M, Fang M, Stolyar L, Walsh J, Kerr G, Raychaudhuri S, Reimold A, Wong M. Race and Ethnicity as Predictors of Diagnostic Delay in Psoriatic Arthritis and Axial Spondyloarthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/race-and-ethnicity-as-predictors-of-diagnostic-delay-in-psoriatic-arthritis-and-axial-spondyloarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/race-and-ethnicity-as-predictors-of-diagnostic-delay-in-psoriatic-arthritis-and-axial-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology